Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen

Pyxis Oncology (NASDAQ:PYXS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other research analysts also recently issued research reports about the stock. HC Wainwright raised their target price on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Wells Fargo & Company raised their target price on Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pyxis Oncology in a research note on Friday, September 25th. Royal Bank Of Canada increased their price objective on shares of Pyxis Oncology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Wedbush decreased their target price on Pyxis Oncology from $8.00 to $7.00 and set an “outperform” rating on the stock in a research note on Friday. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $8.71.

Pyxis Oncology Stock Up 3.1%

Shares of PYXS opened at $1.66 on Friday. Pyxis Oncology has a fifty-two week low of $1.03 and a fifty-two week high of $5.55. The business’s 50-day moving average is $2.51 and its two-hundred day moving average is $2.16.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03. On average, analysts anticipate that Pyxis Oncology will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Commonwealth Equity Services LLC boosted its holdings in Pyxis Oncology by 14.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock worth $114,000 after buying an additional 6,295 shares during the period. T3 Companies LLC acquired a new stake in Pyxis Oncology during the 3rd quarter worth approximately $61,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Pyxis Oncology by 22.0% in the first quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after acquiring an additional 160,300 shares during the period. 39.07% of the stock is currently owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.